In aseptic parenteral manufacturing campaigns for porcine and bovine immunomodulation, Qishao Zengmian Powder Veterinary Grade API is initially dispersed rather than solubilised because the milled botanical dry extract retains a measurable insoluble fraction. No harmonised monograph currently fixes a single addition rate; the loading ranges stated for each route are working ranges derived from similar dry extract formulation platforms and must be verified by stability studies under the target market authorisation. The powder is passed through a 100–150 µm screen before wetting in water for injection at 35–40 °C; the resulting suspension is pH-adjusted to 5.5–6.5 with 0.1 M citrate or phosphate buffer because alkalinity accelerates polymerisation of polyphenolic fractions. A depyrogenation step using 0.05% activated carbon or ultrafiltration may be required when the incoming endotoxin load exceeds 0.25 EU/mL. Particle size distribution is monitored by laser diffraction according to ISO 13320:2020 to maintain D90 below 180 µm before wetting. Filtration is staged through 0.45 µm and 0.22 µm PES membranes, and terminal sterilisation is applicable only if forced degradation data demonstrate marker compound recovery above 95% after 121 °C for 15 min; otherwise, aseptic filling under Grade A laminar flow is the acceptable control strategy under EU Regulation 2019/6 and 21 CFR 210/211. Residual solvent and elemental impurity limits follow VICH GL18 and ICH Q3D, with attention to arsenic and lead in botanical extracts. The addition ratio for exploratory injectable formulations has been evaluated at 0.5–2.0% w/v; published data for this specific configuration is limited, and the upper boundary is constrained by syringeability and visible particle formation.

The injectable route is sensitive to extractables from elastomeric closures; bromobutyl stoppers are pre-washed and siliconised with low-viscosity dimethicone at 0.5–1.0% application rate, and headspace oxygen is maintained below 2.0% by nitrogen overlay. Terminal sterilisation validation uses a saturated steam autoclave fitted with 12 thermocouples and an F0 value of 8–12 min; if F0 cannot be achieved without marker degradation above 10%, aseptic filling is selected. Visible particle inspection on a fully automated line with 99% detection probability at 50 µm is used for release, and subvisible particle counts are controlled to ≤6,000 particles per vial at ≥10 µm and ≤600 at ≥25 µm according to Ph. Eur. 0520. Published stability studies for this specific API in multi-dose injectable matrices are limited; a bracketing protocol covering 25 °C/60% RH and 40 °C/75% RH is applied for at least 6 months because botanical polyphenol fractions may increase particle size on storage. Terminal finished product types include 50 mL and 100 mL Type I glass vials, bromobutyl rubber stoppers, aluminium flip-off seals, and lyophilised monodose vials for companion animal clinics.

Does Direct Compression Preserve Botanical API Dose Uniformity Across 10 mm Tooling?

Tablet and capsule line qualification for this API begins not with blend uniformity but with moisture sorption isotherm mapping because the dry extract can gain 3–5% mass at 60% relative humidity and a pre-drying step is required when loss on drying exceeds 6.0%. The powder is screened through 0.8 mm mesh and blended with microcrystalline cellulose and pregelatinised starch in a twin-shell blender at 20 rpm for 15 min; magnesium stearate is added only in the final 2 min to avoid excessive coverage. Direct compression is limited to formulations with active loading up to 10.0% w/w, above which flow function coefficient drops below 4 and segregation potential increases. For higher active loads between 10.0% and 20.0% w/w, roll compaction at 30–50 kN/cm is used to produce granules with bulk density 0.45–0.60 g/cm³. Tablet compression runs on a rotary press with 8–12 stations, 10 mm flat-faced bevel-edge tooling, target hardness 5–8 kp, friability ≤1.0%, and disintegration time ≤15 min in 1 L simulated gastric fluid at 37 °C. Compliance is anchored to Ph. Eur. 0478, USP <905>, USP <711>, and EU Regulation 2019/6. Compatibility screening excludes primary amine-based binders and alkaline disintegrants because they accelerate polyphenol oxidation and increase tablet browning at accelerated stability conditions. Terminal finished product types include 250 mg and 500 mg oral tablets, 300 mg hard gelatin capsules, and chewable tablets for companion animal clinics; capsule filling uses a dosator or tamping-style machine with fill weight control at ±5% relative standard deviation. Published data for this specific API in chewable matrices is limited, so hardness and palatability masking must be confirmed by pilot batch.

When the API is routed into high-throughput poultry integrator lines, the critical process boundary shifts from content uniformity to water solubility and filterability because drinking-water administration must pass through nipple-drinker filters and proportioners. The powder is pre-dispersed in 10–20% of the final water volume at 25–30 °C, then transferred into a header tank with continuous recirculation at 1.5–2.0 m/s flow velocity to prevent sedimentation. The addition rate in drinking water is commonly evaluated at 0.05–0.5 g/L, while oral powder top dressing on finished feed is tested at 0.5–2.0 kg/ton; published data for this specific configuration is limited, and the upper water rate is constrained by grittiness and poor palatability in broiler lines. Water quality controls include free chlorine below 3 ppm, pH 6.0–7.0, and hardness below 300 mg/L CaCO₃ because polyphenolic fractions can form complexes with divalent cations. Prepared solutions are used within 6 h; holding beyond this period increases aerobic plate count above 10⁴ CFU/mL when no preservative system is permitted. Compliance follows EU Regulation 2019/6, 21 CFR Part 558 for medicated feed adjunct evaluation, and ISO 22000:2018 feed safety management; analytical release is performed by HPLC marker fingerprinting under ICH Q2(R2) or VICH GL2. Terminal finished product types include 1 kg and 5 kg laminated foil sachets, 25 kg drums with polyethylene liners, and 10 L intermediate bulk containers for integrator farm dosing pumps.

When Steam Conditioning Exceeds 65 °C and Moisture Peaks in the Pellet Die

Conditioning prior to pellet pressing exposes the API to a transient moisture-temperature envelope in which the botanical polyphenol fraction can undergo oxidative coupling and Maillard-type browning when reducing carbohydrates are present in the premix carrier. The premix is prepared at an active concentration of 5.0–10.0% w/w on a corn cob or calcium carbonate carrier; final feed inclusion is evaluated at 1.0–3.0 kg/ton in swine grower-finisher rations, while published data for this specific configuration is limited and the upper limit must be confirmed by liver residue studies if the product is positioned as a zootechnical feed additive. Mixing in a ribbon blender with a coefficient of variation target below 5% after 10 min is followed by steam conditioning at 65–75 °C for 20–40 s, then pelleting through a 3.0–4.5 mm annular die. Post-pellet cooling to ≤25 °C and moisture ≤13% is required because residual heat accelerates caking and marker degradation during warehousing.

The pellet mill is operated with a die speed of 150–250 rpm and specific energy consumption 15–25 kWh/ton for finisher rations, while addition of the API at the upper end of the range can increase die temperature by 3–5 °C due to frictional heating. A counterflow cooler with an air volume sized at 1,000–1,500 m³/h per ton processed reduces pellet temperature to ≤25 °C within 15–20 min; moisture re-equilibration to ≤13% prevents condensation inside bulk silos. Because botanical dry extract lots may vary in marker compound content, the premix active concentration is adjusted after HPLC assay, and a verification programme consisting of three consecutive production batches is used to confirm homogeneity before routine release. The finished premix is incompatible with high-alkalinity mineral supplements containing quicklime or concentrated urea solutions due to pH shift above 8.0 and polyphenol oxidation; such combinations should be separated in feed sequencing. Compliance is anchored to FAMI-QS, GMP+ BA2, ISO 22000:2018, and EU Regulation 2019/6 where claims are medical rather than zootechnical. Terminal finished product types include 25 kg multi-wall paper bags with inner polyethylene liner, 500 kg big bags, and pelleted complete feed delivered in bulk or 40 kg sacks.

Orally administered granules intended for adult ruminants require a different granule porosity target than monogastric premixes because rumen retention time and ruminal pH affect release from the hydrated botanical matrix. The API is wet-granulated in a high-shear granulator at an active loading of 10.0–30.0% w/w with a binder system of povidone K-30 or pregelatinised maize starch, impeller speed 150–250 rpm, and water addition 8.0–12.0% over 90–120 s. End-point torque is controlled at 20–35 Nm on a 600 L machine to avoid overwetting, which produces granules that fracture during fluid-bed drying at 45–55 °C. Drying continues until loss on drying is ≤4.0%; the dry granules are screened to 0.5–1.0 mm and final active content is confirmed by HPLC with a target assay 95.0–105.0% of label claim. Flow through a gravity-fed drench cup requires bulk density 0.50–0.70 g/cm³ and Hausner ratio below 1.25 according to USP <616> to prevent bridging in 5 kg pails. Compliance follows Ph. Eur. 0499, EU Regulation 2019/6, and stability testing under VICH GL4; microbial limits follow Ph. Eur. 5.1.4 for oral preparations. Published data for this specific API in ruminant granule matrices is limited, so palatability and rumen degradation kinetics must be confirmed with fistulated-cow models under ethically approved protocols. Terminal finished product types include 200 g sachets, 1 kg jars, and 5 kg pails; the granules may also be mixed into a drench suspension at the farm.

Parenteral and Oral Solution Filtration, Sterility Assurance and pH Control

Large-volume oral solutions and drench preparations fall under a different regulatory branch than solid dosage forms because solubility, pH drift, and microbial challenge become the defining release criteria rather than compressibility or granule friability. The API is incorporated at 0.2–1.0% w/v in oral solutions and up to 5.0% w/w in oral drench pastes; published data for this specific configuration is limited, and the upper limit in drench pastes is constrained by viscosity build-up above 5,000 mPa·s at 20 °C. Mixing is performed in a 500 L 316L stainless steel reactor with bottom-mounted rotor-stator dispersion at 1,500 rpm for 20 min, followed by pH adjustment to 5.0–6.0 with citric acid monohydrate. Clarification through 0.45 µm polypropylene depth filters is followed by 0.22 µm sterilizing-grade filtration for parenteral intermediates, with bubble-point testing before and after filling; terminal heat sterilisation is avoided unless forced degradation demonstrates marker recovery above 98% after 115 °C for 30 min. Aseptic filling is conducted in Grade A with unidirectional airflow velocity 0.36–0.54 m/s; amber polyethylene terephthalate bottles are used because UV exposure accelerates photodegradation of the botanical pigment fraction. Compliance follows Ph. Eur. 0520, Ph. Eur. 5.1.1, USP <71>, ICH Q3D, and EU Regulation 2019/6.

For multi-dose oral solutions, a preservative system is selected only after efficacy testing according to Ph. Eur. 5.1.3; sodium benzoate at 0.1–0.2% w/v and potassium sorbate at 0.1–0.2% w/v are evaluated at pH 5.0–6.0 because benzyl alcohol is usually excluded from neonatal livestock products. The filled amber bottles are induction-sealed and stored at ≤30 °C; freeze-thaw cycling at −5 °C to +40 °C is performed to detect precipitation or pH drift. For parenteral intermediates, the sterile solution is filled under inert gas with oxygen headspace below 1.0% and the finished vials are held for 14 days at 25 °C to detect slow-germinating fungal contaminants before release. Terminal finished product types include 1 L and 5 L HDPE jerrycans for farm use, 100 mL oral drench bottles, and 10 mL unit-dose oral syringes for neonatal livestock.